1.
Ann Rheum Dis
; 81(1): 143-145, 2022 01.
Article
En
| MEDLINE
| ID: mdl-34556483
Antirheumatic Agents/adverse effects , Arthritis/drug therapy , Biological Products/adverse effects , COVID-19/chemically induced , Abatacept/adverse effects , Administration, Intravenous , Aged , Antibodies, Monoclonal, Humanized/adverse effects , B-Lymphocytes , Biological Products/administration & dosage , Biological Products/therapeutic use , Female , Hospitalization , Humans , Infliximab/adverse effects , Male , Middle Aged , Patient Acuity , Risk Factors , Rituximab/adverse effects , SARS-CoV-2